Article
Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2021
Puhalla Shannon L, Diéras Véronique, Arun Banu K, Kaufman Bella, Wildiers Hans, Han Hyo S, Ayoub Jean-Pierre, Stearns Vered, Yuan Yuan, Helsten Teresa, Riley-Gillis Bridget, Murphy Erin, Kundu Madan G, Wu Meijing, Maag David, Ratajczak Christine K, Ramathal Cyril Y, Friedlander Michael
Abstract excerpt
PURPOSE: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover veliparib monotherapy after disease progression on placebo plus carboplatin/paclitaxel. PATIENTS AND METHODS: Eligible patients (N = 513) were randomized 2:1 to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.